Bengaluru, March 03, 2026: KIMS Hospitals becomes the first centre in India to introduce Adaptive Deep Brain Stimulation (aDBS), an advancement in neurotechnology. As the first and only complete sensing-enabled closed-loop systems for patients suffering from Parkinson’s disease. This advanced technology is built on the previously developed Percept™ Platform and is now combined with brain-sensing capabilities (BrainSense™) to give patients a more personalised experience with neuromodulation therapy.
Deep Brain Stimulation (DBS) has been used to ease symptoms of tremor, rigidity and slowness of movement in people with Parkinson’s disease. Earlier versions of these devices delivered constant levels of stimulation. However, the recently developed version of adaptive DBS (or closed-loop DBS) differs from previous iterations in that it can adjust stimulation levels in real time in response to brain signals via local field potentials (specifically oscillations in the beta frequency range). This dynamic adjustment occurs because adaptive DBS recognises fluctuations in brain activity and increases or decreases stimulation automatically, thus limiting the need for human intervention, need for patients or physicians to adjust stimulation levels manually. However, the thresholds and stimulation parameters will be defined and controlled by the specialist doctors.
Speaking about the launch of Adaptive DBS, Dr. Guruprasad Hosurkar, Director & Lead Consultant in Neurology, Head of Parkinson’s Disease and Movement Disorder Programme at KIMS Hospitals, described it as providing some major advantages. First, it significantly reduces the need for patients to manually adjust their device settings, as the system automatically responds to symptom fluctuations. Secondly, studies show that overall stimulation usage will decrease by approximately 50%, which could increase battery life and reduce long-term battery replacement costs. Thirdly, since there is less excess stimulation received during longer periods of time, there may be a reduced risk of developing long-term stimulation-related side effects to the brain tissue surrounding the implant.
The adaptive DBS technology received regulatory approval in the USA first and has since been introduced at select locations throughout the world, including Japan. India received approval earlier this year, with KIMS Hospitals, Bengaluru, among the first hospitals to implement the technology.
Dr. Raghuram Gopalakrishnan, Director & Senior Consultant, Head of Stereotactic and Functional Neurosurgery, said, “In the first phase, we will upgrade select existing DBS patients to the adaptive platform through a software update and advanced programming interface. The hospital plans to implement the new technology for four to five eligible patients in early March. He also explained that AI in medicine has been a significant boost in advancing patient care when used appropriately, and Adaptive DBS is an example of that, where the AI algorithm analyses the waveforms from the neurons and adjusts stimulation parameters accordingly.”
Dr. Nitish Shetty, Managing Director, KIMS Hospitals (Krishna Institute of Medical Sciences), Bengaluru, said, “The introduction of adaptive closed-loop DBS marks a transformative step in how we deliver personalised neurological care at KIMS. By launching this advanced technology in India, we remain committed to developing worldwide standard innovations that will directly impact patient outcomes and enhance quality of life.”
By adopting this new advanced technology, KIMS Hospitals reinforces its commitment to offering cutting-edge, evidence-based neurological care. The introduction of adaptive closed-loop DBS is a significant step towards individualised therapy options for Indian patients with Parkinson’s Disease that will provide a real-time response to their brain’s activity via feedback from their brain.
